- Obesity drug beloranib shows promise in Prader-Willi population in Phase 2 trials
- Study: Whooping cough vaccine may not prevent infection
- Ensuring access to chronic pain medications
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Reports: Bill to extend federal regulations for compounding pharmacies expected to pass House, Senate
SAN DIEGO — A biotech company and a nonprofit organization are looking into new ways to treat patients with the devastating degenerative disorder commonly known as Lou Gehrig's disease.
The ALS Emergency Treatment Fund and Denovo Biomarkers announced Friday a deal to explore the use of personalized medicine in treating patients with the disease, known medically as amyotrophic lateral sclerosis. The two said the approach could accelerate drug development in ALS and other life-threatening disorders.
"This exciting relationship with Denovo Biomarkers may accelerate the development of drugs for ALS and may help us provide useful information for patients and physicians," ALS-ETF managing director Jess Rabourn said.